| pubmed-article:18563186 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0001483 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0549206 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0036945 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0042149 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0078058 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0226378 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0232338 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0042401 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C1256770 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0011209 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0205276 | lld:lifeskim |
| pubmed-article:18563186 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:18563186 | pubmed:issue | 19 | lld:pubmed |
| pubmed-article:18563186 | pubmed:dateCreated | 2008-9-16 | lld:pubmed |
| pubmed-article:18563186 | pubmed:abstractText | Impaired materno-placental perfusion causes two important obstetric complications, fetal growth restriction and preeclampsia. This study investigated whether adenoviral vector-mediated overexpression of vascular endothelial growth factor (VEGF) in the uterine arteries (UtAs) increases uterine artery blood flow (UBF). First-generation adenovirus vectors (5 x 10(11) particles) containing the VEGF gene (Ad.VEGF-A or -D) or the beta-galactosidase reporter gene (Ad.lacZ) were injected into the UtAs of pregnant sheep (n=6) at 88-102 days of gestation (term=145 days). UBF was measured using Doppler sonography before, and 4-7 days after injection. Mean UBF increased significantly from 233+/-156 (s.d.) ml min(-1) to 753+/-415 ml min(-1) following Ad.VEGF-A injection (P=0.005, n=5); Ad.lacZ infection had no significant effect. Organ bath experiments on uterine arterial sections 4-7 days after injection showed that, compared with Ad.lacZ vessels, Ad.VEGF-A-transduced vessels had a reduced contractile response to phenylephrine (E max 148+/-10.9 vs E max 228.2+/-27.5, P<0.05) but increased relaxation with bradykinin (pD2 (-log EC50) values 9.11+/-0.01 vs 8.65+/-0.11, P<0.05). Injection of Ad.VEGF-A into the UtAs increases UBF by enhancing vasodilatation. This may provide the basis for therapy in pregnancies complicated by uteroplacental insufficiency. | lld:pubmed |
| pubmed-article:18563186 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18563186 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18563186 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18563186 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18563186 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18563186 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18563186 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18563186 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:18563186 | pubmed:issn | 1476-5462 | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:MartinJJ | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:RodeckC HCH | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:CoonWW | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:BoydMM | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:MehtaVV | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:DavidA LAL | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:ZacharyII | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:PeeblesD MDM | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:WigleyVV | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:TorondelBB | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:Abi-NaderKK | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:BuckleyS M... | lld:pubmed |
| pubmed-article:18563186 | pubmed:author | pubmed-author:NaderK AKA | lld:pubmed |
| pubmed-article:18563186 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18563186 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:18563186 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18563186 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18563186 | pubmed:pagination | 1344-50 | lld:pubmed |
| pubmed-article:18563186 | pubmed:dateRevised | 2008-12-30 | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:meshHeading | pubmed-meshheading:18563186... | lld:pubmed |
| pubmed-article:18563186 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18563186 | pubmed:articleTitle | Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep. | lld:pubmed |
| pubmed-article:18563186 | pubmed:affiliation | Prenatal Gene Therapy Group, Institute for Women's Health, Royal Free and University College London Medical School, London, UK. a.david@ucl.ac.uk | lld:pubmed |
| pubmed-article:18563186 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18563186 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18563186 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18563186 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18563186 | lld:pubmed |
